Cardiac RAGE in sepsis call toll free for anti-rage

Circulation Research

Volumn 102, Issue 10, 2008, Pages 1153-1154

  Feuerstein, Giora Z ^a  

^a PFIZER INC   (United States)

Author keywords

Cardiac failure; RAGE; S1008 9; Sepsis; Toll like receptor

Indexed keywords

ACTIVATED PROTEIN C; ADVANCED GLYCATION END PRODUCT RECEPTOR; BLOOD CLOTTING FACTOR 10A; CALGRANULIN A; CALGRANULIN B; CORTICOSTEROID; ICOSANOID; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIBODY;

DEATH; EDITORIAL; ENDOTOXEMIA; FLUID RESUSCITATION; GENE MUTATION; GENETIC PREDISPOSITION; HEART MUSCLE CONTRACTILITY; HEMOSTASIS; HYPOTENSION; IMMUNE RESPONSE; INCIDENCE; INFECTION; INFLAMMATION; MACROPHAGE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; ANIMAL; HEART FAILURE; HUMAN; IMMUNOLOGY; NOTE; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES; CALGRANULIN A; CALGRANULIN B; HEART FAILURE; HUMANS; RECEPTORS, IMMUNOLOGIC; SEPSIS; TOLL-LIKE RECEPTOR 4;

EID: 45149083881     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.177261     Document Type: Editorial

References (15)

1. Vincent J-L, Abraham E. The last 100 years of sepsis. Crit Care Med. 2006;173:256-263.
2. Martin GS, Mannino DM, Eaton S, Moss M. Epidemiology of sepsis in the United States from 1979-2000. N Engl J Med. 2003;348:1546-1557.
3. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, for the International Surviving Sepsis Campaign Guidelines Committee. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36: 296-327.
4. Van Zoelen MA, van der Poll T. Targeting RAGE in sepsis. Critical Care. 2008;12:103.
5. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, Martin E, Weigand MA. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care. 2008;12:201.
6. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Invest Drugs. 2006;7:985-991.
7. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Gröne HJ, Kurschus FC, Schmidt AM, Yan SD, Martin E, Schleicher E, Stern DM, Hämmerling GJ, Nawroth PP, Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004;113:1641-1650.
8. Basta G. Receptor for advanced glycation end products and atherosclerosis: from basic mechanism to clinical implications. Atherosclerosis. 2008;196:9-21.
9. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, Zou YS, Yan SF, Ann Marie Schmidt AM, Ramasamy R. Receptor for advanced-glycation end products: key modulator of myocardial ischémie injury. Circulation. 2006;113:1226-1234.
10. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin induced cardiomyocytes dysfunction via receptor for advanced glycation end products. Circ Res. 2008;102:1239-1246.
11. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappaB dependent inflammation response. Cardiovasc Res. 2006;72:384-393.
12. Most P, Remppis A, Pleger ST, Loffler E, Ehlermann P, Bernotat J, Kleuss C, Heierhorst J, Ruiz P, Witt H, Karczewski P, Mao L, Rockman HA, Duncan SJ, Katus HA, Koch WJ. Transgenic over expression of the Ca2 +-binding protein S100A1 in the hear leads to increased in vivo myocardial contractile performance. J Biol Chem. 278:33809-33817.
13. Pleger ST, Remppis A, Heidt B, Volker M, Chuprun JK, Kuhn M, Zhou RH, Gao E, Szabo G, Weichenhan D, Muller OJ, Eckhart AD, Katus HA, Koch WJ, Most P. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther. 2005;12:1120-1129.
14. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflmmatory activities of S100 proteins S100A8, S100A9 and S100A8/A9 induced neu-trophil chemotaxis and adhesion. J Immunol. 2003;170:3233-3242.
15. Hoffmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S 100/calgranulin polypeptide. Cell. 1999;97:889-901.